Form 4: Veracyte CCO Sells Shares Under 10b5-1 Plan

Veracyte's Chief Commercial Officer, John Leite, sold 5,260 shares of common stock for approximately $35.19 per share under a pre-arranged 10b5-1 trading plan.

Summary

• John Leite, the Chief Commercial Officer-CLIA of VERACYTE, INC. (VCYT), reported a sale of common stock.
• The transaction involved the disposition of 5,260 shares of VCYT common stock.
• The shares were sold at a weighted average price of $35.1868 per share, with individual sale prices ranging from $35.00 to $35.53.
• The sale was executed on March 4, 2026.
• Following this transaction, John Leite beneficially owns 107,580 shares of Veracyte common stock.
• The transaction was conducted pursuant to a Rule 10b5-1 plan, which was adopted by Mr. Leite on June 9, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which typically does not signal a change in management's outlook on the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 plan are pre-scheduled transactions designed to allow insiders to sell shares without concerns about insider trading allegations. Such sales are generally considered less indicative of management's sentiment about the company's future prospects compared to unscheduled open market sales, as the decision to sell was made at an earlier date.

Key Dates

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Stock Sale, John Leite, Chief Commercial Officer, 10b5-1 Plan